MTOS Technology is actively seeking strategic partnerships for technology transfer
MTOS-I is a breakthrough broad-spectrum antiviral new drug designed for the treatment of viral infectious diseases, including SARS-CoV-2, with significant efficacy.
✔ Enhancement of immune function with significant antiviral effect
✔ Good safety profile
✔ Broad-spectrum applications
✔ Virus prevention
✔ Low production cost
Animal tests confirm that MTOS-I significantly improves humoral immunity, cellular immunity, and phagocytosis in normal and tumor-bearing S180 mice.
Extensive human use since 1997 shows significant therapeutic effects, including quick action and short course of treatment for hepatitis, herpes zoster, influenza, and other viral infections.
Used prophylactically to prevent SARS-CoV-2 infection among medical staff, the elderly, and children.